Metabolic–Renal Divergence in Diabetic Patients Three Months After COVID-19: Evidence from a Real-World Cohort

International Diabetes Federation. Global diabetes burden 2024 report. Diabetes Res Clin Pract. 2024;201:110678. doi: 10.1016/j.diabres.2024.110678.

Pal R, Banerjee M. COVID-19 and glycemic control: longitudinal outcomes in diabetes. Front Endocrinol (Lausanne). 2023;14:1187432. doi: 10.3389/fendo.2023.1187432.

McCrimmon RJ, Das AK. Glycemic variability and outcomes in COVID-19. Diabetes Res Clin Pract. 2024;210:110465. doi: 10.1016/j.diabres.2024.110465.

Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of long COVID and metabolic consequences. BMJ. 2023;381:e072452. doi: 10.1136/bmj-2022-072452.

Khunti K, Gomes MB, Pocock S, Shestakova MV, Pintat S, Fenici P, et al. Therapeutic inertia in diabetes care: 2023 update. Diabetes Obes Metab. 2023;25(4):937–949. doi: 10.1111/dom.14942. DOI: https://doi.org/10.1111/dom.14942

Son JW, Lee YH, Kim YG, Park CY, Kim DJ, Lee BW, et al. Therapeutic inertia and diabetes outcomes. J Clin Endocrinol Metab. 2024;109(3):e927–e936. doi: 10.1210/clinem/dgad821.

Qin YY, Zhu L, Cai J, Liu Y, Chen Z, Wang X, et al. Post-COVID-19 renal outcomes. Nephrol Dial Transplant. 2024;39(7):1115–1127. doi: 10.1093/ndt/gfad059. DOI: https://doi.org/10.1093/ndt/gfad059

Greenwood SA, Oliveira BA, Asgari E, Ayis S, Baker LA, Beckley-Hoelscher N, et al. A randomized trial of intravenous iron supplementation and exercise on exercise capacity in iron-deficient nonanemic patients with CKD. Kidney Int Rep. 2023;8(8):1496-1505. doi: 10.1016/j.ekir.2023.05.002. DOI: https://doi.org/10.1016/j.ekir.2023.05.002

Agarwal R, Gansevoort RT, Rizk DV, Levin A, Pecoits-Filho R, Levey AS, et al. Chronic kidney disease after COVID-19. Kidney Int. 2023;104(1):7–19. doi: 10.1016/j.kint.2023.02.012 DOI: https://doi.org/10.1016/j.kint.2023.02.012

American Diabetes Association Professional Practice Committee. Standards of care in diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1–S350. doi: 10.2337/dc24-Sint. DOI: https://doi.org/10.2337/dc24-SINT

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA, Adler AI. Impact of HbA1c reduction on microvascular outcomes. Diabetologia. 2023;66(6):987–995. doi: 10.1007/s00125-023-05834-2.

McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Clinical inertia in diabetes. Mayo Clin Proc. 2023;98(5):913–925. doi: 10.1016/j.mayocp.2023.01.021. DOI: https://doi.org/10.1016/j.mayocp.2023.01.021

Gupta A, Kark JD, Shochat T, Tzur D, Afek A, Grossman E, et al. Hypertension and diabetes: integrative risk management. J Clin Hypertens. 2024;26(5):487–496. doi: 10.1111/jch.14678. DOI: https://doi.org/10.1111/jch.14678

Wu J, Zhang P, Yang X, Liu Y, Chen H, Li Z, et al. Impact of hypertension on glycemic outcomes. Am J Hypertens. 2023;36(11):990–999. doi: 10.1093/ajh/hpad082. DOI: https://doi.org/10.1093/ajh/hpad082

Sterling KL, Shapiro BP, Cooper-DeHoff RM, Carter BL, Calhoun DA, Bakris GL. RAAS blockade and metabolic modulation. Curr Diab Rep. 2023;23(12):600–614. doi: 10.1007/s11892-023-01534-2.

Al-Aly Z, Bowe B, Xie Y. Post-acute COVID organ sequelae. Nat Med. 2024;30(1):35–45. doi: 10.1038/s41591-023-02618-6.

Banerjee S, Sulaiman R, Hussain N, Ahmed A, Patel K, Sharma R, et al. Clinical pharmacy interventions reduce therapeutic inertia. Diabetes Ther. 2025;16(4):985–1001. doi: 10.1007/s13300-025-01560-1.

Pantalone KM, Hobbs TM, Wells BJ, Kong SX, Kattan MW, Bouchard J, et al. Real-world therapeutic inertia and glycemic outcomes. Diabetes Ther. 2023;14(7):1385–1398. doi: 10.1007/s13300-023-01402-3.

Pugliese G, Solini A, Bonora E, Ceriello A, Mannucci E, Monami M, et al. Integrated cardiometabolic care in diabetes. Nat Rev Endocrinol. 2025;21(1):12–30. doi: 10.1038/s41574-024-00823-4.

Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al. Management of diabetes in the context of COVID-19. Lancet Diabetes Endocrinol. 2024;12(3):176–188. doi: 10.1016/S2213-8587(23)00284-6.